Survival benefit of high dose therapy over sequential chemotherapy in poor risk aggressive non-Hodgkin's lymphoma. Final analysis of the prospective LNH87-2 protocol. A gela study.

被引：0
|
作者：
Haioun, C [1 ]
Lepage, E [1 ]
Gisselbrecht, C [1 ]
Salles, G [1 ]
Coiffier, B [1 ]
Brice, P [1 ]
Bosly, A [1 ]
Morel, P [1 ]
Nouvel, C [1 ]
Tilly, H [1 ]
Lederlin, P [1 ]
Sebban, C [1 ]
Briere, J [1 ]
Gaulard, P [1 ]
Reyes, F [1 ]
机构：
[1] Hop Henri Mondor, F-94010 Creteil, France
来源：
BLOOD | 1999年 / 94卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2711
引用
收藏
页码：610A / 610A
页数：1
相关论文
共 50 条
  • [41] Chemotherapy plus interferonα-2b vs. high-dose therapy for response consolidation in low grade non-Hodgkin's lymphoma:: Results of a retrospective case control study.
    Sanz-Rodriguez, C
    Sanchez, A
    Rodriguez, F
    Gandarillas, M
    Conde, E
    Arranz, R
    BLOOD, 2000, 96 (11) : 791A - 791A
  • [42] Frontline therapy with early intensification and autologous stem cell transplantation versus conventional chemotherapy in unselected high-risk, aggressive non-Hodgkin's lymphoma patients: A prospective randomized GEMOH report
    Baldissera, RC
    Nucci, M
    Vigorito, AC
    Maiolino, A
    Simoes, BP
    Lorand-Metze, I
    Aranha, FJP
    Miranda, ECM
    Pagnano, KBB
    Ruiz, MA
    Moraes, AAJG
    De Souza, CA
    ACTA HAEMATOLOGICA, 2006, 115 (1-2) : 15 - 21
  • [43] High-risk aggressive non-Hodgkin's lymphoma patients treated upfront with high-dose sequential chemotherapy and autograft: the long-term outcome is markedly influenced by presentation with aaIPI score 2 vs. 3
    Cuttica, A
    Zallio, F
    Ladetto, M
    Di Nicola, M
    Caracciolo, D
    Magni, M
    Marinone, C
    Dell'Aquila, M
    Boccadoro, M
    Pileri, A
    Gianni, M
    Tarella, C
    BONE MARROW TRANSPLANTATION, 2003, 31 : S7 - S7
  • [44] Tandem high-dose therapy followed by autologous stem-cell transplantation for refractory or relapsed high grade non-Hodgkin's lymphoma with poor prognosis factors: a prospective pilot study
    Le Gouill, S
    Moreau, P
    Morineau, N
    Harousseau, JL
    Milpied, N
    HAEMATOLOGICA, 2002, 87 (03) : 333 - 334
  • [45] Aggressive Chemotherapy (CHOEP-14) and Rituximab or High-Dose Therapy (MegaCHOEP) and Rituximab for Young, High-Risk Patients with Aggressive B-Cell Lymphoma: Results of the MegaCHOEP Trial of the German High - Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)
    Schmitz, Norbert
    Nickelsen, Maike
    Ziepert, Marita
    Haenel, Matthias
    Borchmann, Peter
    Viardot, Andreas
    Nickenig, Christina
    Bentz, Martin
    Peschel, Christian
    Truemper, Lorenz
    Loeffler, Markus
    Pfreundschuh, Michael
    Glass, Bertram
    BLOOD, 2009, 114 (22) : 168 - 168
  • [46] Rituximab vs. nothing after high-dose consolidative first-line chemotherapy (HDC) with autologous stem cell transplantation in poor risk diffuse large B-cell lymphoma.: Results of the first interim analysis of the randomized LNH98-B3 GELA study.
    Haioun, C
    Mounier, N
    Emile, JF
    Feugier, P
    Coiffier, B
    Tilly, H
    Recher, C
    Fermé, C
    Gabarre, J
    Herbrecht, R
    Morschhauser, F
    Gisselbrecht, C
    BLOOD, 2003, 102 (11) : 399A - 399A
  • [47] A phase II trial of front-line double high dose chemotherapy (HDCT) with DICEP then BEAM and autologous stem cell transplantation (ASCT) as induction therapy for poor prognosis aggressive non-Hodgkin's lymphoma (NHL).
    Stewart, DA
    Glück, S
    Chaudhry, A
    Morris, D
    Parameswaran, R
    Brown, C
    Balogh, A
    Valentine, K
    Jones, A
    Ruether, B
    Blahey, W
    Thaell, T
    Russell, JA
    BLOOD, 2002, 100 (11) : 645A - 645A
  • [48] High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: A prospective randomized Italian multicenter study
    Martelli, M
    Vignetti, M
    Zinzani, PL
    Gherlinzoni, F
    Meloni, G
    Fiacchini, M
    DeSanctis, V
    Papa, G
    Martelli, MF
    Calabresi, F
    Tura, S
    Mandelli, F
    JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (02) : 534 - 542
  • [49] Fludarabine compared with CVP chemotherapy in newly diagnosed patients with stages III and IV low grade malignant non-Hodgkin's lymphoma. Final analysis of a prospective randomized phase III intergroup study in 381 patients.
    Hagenbeek, A
    Eghbali, H
    Monfardini, S
    Resegotti, E
    Hoskin, J
    de Wolf-Peeters, C
    McLennan, K
    Staab-Renner, E
    Schott, A
    Teodorovic, I
    Negrouk, A
    van Glabbeke, M
    Marcus, R
    BLOOD, 2001, 98 (11) : 843A - 843A
  • [50] Rituximab versus nothing after high-dose consolidative first-line chemotherapy with autologous stem cell transplantation in poor risk diffuse large B-cell lymphoma.: Results of the first interim analysis of the randomised LNH98-B3 GELA study
    Haioun, C
    Mounier, N
    Emile, JF
    Feugier, P
    Coiffier, B
    Tilly, H
    Recher, C
    Fermé, C
    Gabarre, J
    Herbrecht, R
    Morschhauser, F
    Gisselbrecht, C
    BONE MARROW TRANSPLANTATION, 2004, 33 : S5 - S5
12345